<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2151-4658</journal-id><journal-id journal-id-type="publisher-id">ACR</journal-id><journal-title-group><journal-title>Arthritis Care &#x00026; Research</journal-title></journal-title-group><issn pub-type="ppub">2151-464X</issn><issn pub-type="epub">2151-4658</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27565000</article-id><article-id pub-id-type="pmc">5413813</article-id><article-id pub-id-type="doi">10.1002/acr.23004</article-id><article-id pub-id-type="publisher-id">ACR23004</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Tofacitinib in Combination With Conventional Disease&#x02010;Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient&#x02010;Reported Outcomes From a Phase III Randomized Controlled Trial</article-title><alt-title alt-title-type="right-running-head">PROs From a Study of Tofacitinib With DMARDs in Patients With Active RA</alt-title><alt-title alt-title-type="left-running-head">Strand et al</alt-title></title-group><contrib-group><contrib id="acr23004-cr-0001" contrib-type="author"><name><surname>Strand</surname><given-names>Vibeke</given-names></name><xref ref-type="aff" rid="acr23004-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acr23004-cr-0002" contrib-type="author"><name><surname>Kremer</surname><given-names>Joel M.</given-names></name><xref ref-type="aff" rid="acr23004-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="acr23004-cr-0003" contrib-type="author"><name><surname>Gruben</surname><given-names>David</given-names></name><xref ref-type="aff" rid="acr23004-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="acr23004-cr-0004" contrib-type="author"><name><surname>Krishnaswami</surname><given-names>Sriram</given-names></name><xref ref-type="aff" rid="acr23004-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="acr23004-cr-0005" contrib-type="author"><name><surname>Zwillich</surname><given-names>Samuel H.</given-names></name><xref ref-type="aff" rid="acr23004-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="acr23004-cr-0006" contrib-type="author" corresp="yes"><name><surname>Wallenstein</surname><given-names>Gene V.</given-names></name><address><email>gene.wallenstein@pfizer.com</email></address><xref ref-type="aff" rid="acr23004-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="acr23004-aff-0001"><label><sup>1</sup></label><institution>Stanford University School of Medicine</institution><named-content content-type="city">Palo Alto</named-content><named-content content-type="country-part">California</named-content></aff><aff id="acr23004-aff-0002"><label><sup>2</sup></label><institution>Albany Medical College</institution><named-content content-type="city">Albany</named-content><named-content content-type="country-part">New York</named-content></aff><aff id="acr23004-aff-0003"><label><sup>3</sup></label><institution>Pfizer Inc</institution><named-content content-type="city">Groton</named-content><named-content content-type="country-part">Connecticut</named-content></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence to Gene V. Wallenstein, PhD, Specialty Care Medicines Development Group, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340. E&#x02010;mail: <email>gene.wallenstein@pfizer.com</email>.</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>69</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/acr.v69.4</issue-id><fpage>592</fpage><lpage>598</lpage><history><date date-type="received"><day>02</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>16</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>02</day><month>8</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017, American College of Rheumatology <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016, The Authors. Arthritis Care &#x00026; Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACR-69-592.pdf"/><abstract><sec id="acr23004-sec-0001"><title>Objective</title><p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient&#x02010;reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease&#x02010;modifying antirheumatic drugs (DMARDs).</p></sec><sec id="acr23004-sec-0002"><title>Methods</title><p>In a 12&#x02010;month, phase III randomized controlled trial (ORAL Sync), patients (n&#x02009;=&#x02009;795) with active RA and previous inadequate response to therapy with &#x02265;1 conventional or biologic DMARD were randomized 4:4:1:1 to tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID, placebo advanced to 5 mg BID, or placebo to 10 mg BID, in combination with stable background DMARD therapy. PROs included patient global assessment of arthritis (PtGA), patient assessment of arthritis pain (Pain), physical function (Health Assessment Questionnaire disability index [HAQ DI]), health&#x02010;related quality of life (Short Form 36 health survey [SF&#x02010;36]), fatigue (Functional Assessment of Chronic Illness Therapy&#x02013;Fatigue [FACIT&#x02010;F]), and sleep (Medical Outcomes Study Sleep [MOS Sleep]).</p></sec><sec id="acr23004-sec-0003"><title>Results</title><p>At month 3, statistically significant improvements from baseline versus placebo were reported in PtGA, Pain, HAQ DI, all 8 SF&#x02010;36 domains, FACIT&#x02010;F, and MOS Sleep with tofacitinib 10 mg BID, and in PtGA, Pain, HAQ DI, 7 SF&#x02010;36 domains, FACIT&#x02010;F, and MOS Sleep with tofacitinib 5 mg BID. Improvements were sustained to month 12. Significantly more tofacitinib&#x02010;treated patients reported improvements of greater than or equal to the minimum clinically important differences at month 3 versus placebo in all PROs, except the SF&#x02010;36 role&#x02010;emotional domain (significant for tofacitinib 10 mg BID).</p></sec><sec id="acr23004-sec-0004"><title>Conclusion</title><p>Patients with active RA treated with tofacitinib combined with background conventional DMARD therapy reported sustained, significant, and clinically meaningful improvements in PROs versus placebo.</p></sec></abstract><funding-group><award-group><funding-source>Pfizer</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="7"/><word-count count="4973"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>acr23004</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:03.05.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="acr23004-note-0001"><p>
<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT00856544.</p></fn><fn id="acr23004-note-0002"><p>Supported by Pfizer.</p></fn><fn id="acr23004-note-0003"><p>Dr. Strand has received consulting fees and is an advisory board member for AbbVie, Amgen, Biogen Idec, BMS, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc, Regeneron, Sanofi, Takeda, UCB, and Vertex (less than $10,000 each), and has received consulting fees from Alder, AstraZeneca, Biotest, Celgene, Celltrion, Corrona LLC, Horizon, Hospira, Incyte, Merck Serono, and Protalex (less than $10,000 each). Dr. Kremer has received consulting fees and research support from AbbVie, Amgen, BMS, Genentech, Pfizer Inc, and UCB (less than $10,000 each), and has received honoraria or speaking fees from AbbVie (less than $10,000). Drs. Gruben, Krishnaswami, Zwillich, and Wallenstein hold shares in Pfizer Inc.</p></fn></fn-group></notes></front><body><sec disp-level="2" id="acr23004-sec-0006"><title>Introduction</title><p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation, joint destruction, and impairment in physical function and health&#x02010;related quality of life (HRQOL) <xref rid="acr23004-bib-0001" ref-type="ref">1</xref>. Improvements in HRQOL, pain, physical function, and fatigue are often more important and meaningful to patients than improvements in composite disease activity measures when evaluating new therapies <xref rid="acr23004-bib-0002" ref-type="ref">2</xref>. This patient preference is reflected by Outcome Measures in Rheumatology, American College of Rheumatology, and European League Against Rheumatism recommendations, and in US Food and Drug Administration guidance, all of which highlight the importance of including clinically relevant patient&#x02010;reported outcomes (PROs) when designing clinical trials of potential RA treatments <xref rid="acr23004-bib-0002" ref-type="ref">2</xref>.</p><boxed-text position="float" content-type="Box" id="acr23004-fea-0001" orientation="portrait"><label>Box 1</label><caption><title>Significance &#x00026; Innovations</title></caption><sec id="acr23004-sec-0033"><p>
<list list-type="bullet" id="acr23004-list-0001"><list-item id="acr23004-li-0001"><p>At month 3, treatment with tofacitinib 5 mg twice daily and 10 mg twice daily resulted in significantly greater improvements from baseline in patient global assessment of arthritis (PtGA), patient assessment of arthritis pain (Pain), and Health Assessment Questionnaire disability index (HAQ DI) score compared with placebo (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). The proportion of patients reporting improvements greater than the minimum clinically important differences in PtGA, Pain, and HAQ DI at month 3 was significantly greater with both doses of tofacitinib versus placebo (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p></list-item><list-item id="acr23004-li-0002"><p>Treatment with tofacitinib 5 mg twice daily and 10 mg twice daily resulted in significant improvements (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) compared with placebo at month 3 in Short Form 36 health survey (SF&#x02010;36) physical component and mental component scores, and 7 of 8 SF&#x02010;36 domains with 5 mg twice daily and all 8 SF&#x02010;36 domains with 10 mg twice daily.</p></list-item><list-item id="acr23004-li-0003"><p>At month 3, significantly greater mean improvements from baseline (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) in Functional Assessment of Chronic Illness Therapy&#x02013;Fatigue and Medical Outcomes Study Sleep scores were reported by patients treated with both doses of tofacitinib versus placebo.</p></list-item></list>
</p></sec></boxed-text><p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib 5 mg twice daily (BID) and tofacitinib 10 mg BID have demonstrated consistent efficacy in reducing the signs and symptoms of RA and produced improvements in PROs, with manageable safety profiles across 6 phase III studies <xref rid="acr23004-bib-0003" ref-type="ref">3</xref>, <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>, <xref rid="acr23004-bib-0005" ref-type="ref">5</xref>, <xref rid="acr23004-bib-0006" ref-type="ref">6</xref>, <xref rid="acr23004-bib-0007" ref-type="ref">7</xref>, <xref rid="acr23004-bib-0008" ref-type="ref">8</xref>, either as monotherapy or in combination with conventional disease&#x02010;modifying antirheumatic drugs (DMARDs).</p><p>The phase III ORAL Sync 12&#x02010;month, randomized controlled trial (RCT) assessed tofacitinib treatment in combination with stably dosed DMARDs in adult patients with active RA and previous inadequate responses to DMARDs and/or biologic DMARDs. Tofacitinib 5 mg BID and 10 mg BID demonstrated rapid, significant, and clinically meaningful improvements in signs and symptoms of RA and physical function, with a safety profile consistent with that observed in other phase III studies <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>. Patients treated with tofacitinib reported mean changes from baseline in the Health Assessment Questionnaire disability index (HAQ DI) and the Functional Assessment of Chronic Illness Therapy&#x02013;Fatigue (FACIT&#x02010;F), comprising 13 items assessing fatigue to give a total score ranging 0&#x02013;52, with higher scores indicating lower fatigue, which were statistically significant compared with placebo <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>. Here we present further PRO data, including HRQOL, from the ORAL Sync study.</p></sec><sec id="acr23004-sec-0007"><sec disp-level="2" id="acr23004-sec-0008"><title>Patients and methods</title><sec id="acr23004-sec-0009"><title>Study design and participants</title><p>ORAL Sync was a 12&#x02010;month, double&#x02010;blind, RCT conducted across 114 centers worldwide between May 2009 and January 2011 (full details of the study design have been reported previously [4]). The trial was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines and was approved by the institutional review board or independent ethics committee for each study center. All patients provided written, informed consent.</p><p>Patients were ages &#x02265;18 years with active RA, defined by &#x02265;4 tender joints, &#x02265;4 swollen joints (68&#x02010; or 66&#x02010;joint count), and an erythrocyte sedimentation rate &#x02265;28 mm/hour (Westergren method) or a C&#x02010;reactive protein level &#x0003e;7 mg/liter. Patients must have had an inadequate response to &#x02265;1 conventional or biologic DMARD before baseline, and continued stable background DMARD therapy throughout the trial. The background DMARD therapy included methotrexate, sulfasalazine, antimalarials, and other nonimmunosuppressive conventional DMARDs, administered alone or in combination. Key exclusion criteria included hemoglobin level &#x0003c;90 grams/liter, hematocrit &#x0003c;30%, leukocyte count &#x0003c;3.0&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/liter, neutrophil count &#x0003c;1.2&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/liter, platelet count &#x0003c;100&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/liter, estimated glomerular filtration rate &#x02264;40 ml/minute per 1.73 m<sup>2</sup> (Cockcroft&#x02010;Gault equation), aspartate aminotransferase or alanine aminotransferase levels &#x0003e;1.5 times the upper limit of normal, and evidence of active infection, including inadequately treated latent or active <italic>Mycobacterium tuberculosis</italic>.</p><p>Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg BID, or placebo advanced to 5 mg or 10 mg BID. At month 3, placebo nonresponders (without &#x02265;20% reductions from baseline in swollen and tender joint counts) were advanced blindly to tofacitinib 5 mg or 10 mg BID; tofacitinib nonresponders at month 3 continued the same treatment. At month 6, all patients still receiving placebo were advanced blindly to tofacitinib 5 mg or 10 mg BID.</p></sec><sec id="acr23004-sec-0010"><title>Assessment of PROs</title><p>All PROs were predefined as secondary trial outcomes and reported at month 3, i.e., before advancement of placebo nonresponders from placebo. Patient global assessment of arthritis (PtGA) and patient assessment of arthritis pain (Pain) used a 100&#x02010;mm visual analog scale (VAS); physical function was assessed by HAQ DI. HRQOL was evaluated using the Medical Outcomes Study (MOS) Short Form 36 health survey (SF&#x02010;36) questionnaire (acute version), comprising 8 domains (physical functioning, role&#x02010;physical, bodily pain, general health, vitality, social functioning, role&#x02010;emotional, and mental health) scored 0&#x02013;100, with higher scores indicating better HRQOL. In addition, the individual SF&#x02010;36 domain scores were combined into physical component summary (PCS) and mental component summary (MCS) scores. Sleep was assessed by the MOS Sleep scale, which queries 6 aspects of sleep to give a total score ranging 12&#x02013;71, with lower scores indicating better sleep.</p><p>Minimum clinically important differences (MCIDs) were defined as &#x02265;10&#x02010;mm decreases from baseline in PtGA and Pain VAS scores, &#x02265;0.22&#x02010;point decrease from baseline in HAQ DI, &#x02265;2.5&#x02010;point increases from baseline in SF&#x02010;36 PCS and MCS scores, &#x02265;5&#x02010;point increases from baseline in SF&#x02010;36 domain scores, and &#x02265;4&#x02010;point increase from baseline in FACIT&#x02010;F <xref rid="acr23004-bib-0009" ref-type="ref">9</xref>. No MCID has been defined for the MOS Sleep scale.</p></sec><sec id="acr23004-sec-0011"><title>Statistical analysis</title><p>Data are presented for the full analysis set (all patients randomized who received &#x02265;1 dose of study drug with &#x02265;1 post&#x02010;baseline assessment) without imputation for missing values. Imputation for missing values is normally applied to model the placebo response, assuming placebo patients had not advanced to tofacitinib treatment after month 3; however, all PROs as secondary outcomes were reported at month 3 before advancement of placebo nonresponders. Estimates of mean changes from baseline for each treatment and mean differences from placebo at month 3 were derived from the model as least squares means (LSMs), with corresponding SEs. The percentages of patients reporting improvements &#x02265;MCID in PROs at month 3 were compared between the tofacitinib and placebo treatment groups (except for MOS Sleep) in a post hoc analysis using the normal approximation to the binomial. Statistical significance was declared at a <italic>P</italic> value of less than or equal to 0.05, with no correction for multiple comparisons. The number needed to treat (NNT) was calculated as 1/(proportion of patients receiving placebo not reporting changes &#x02265;MCID minus the proportion of patients using tofacitinib not reporting improvements &#x02265;MCID).</p></sec><sec id="acr23004-sec-0012"><title>Correlation analyses at month 3</title><p>Correlation analyses (Pearson's correlation) were performed to investigate potential interactions between PROs at month 3. Changes from baseline in each PRO were correlated pairwise, both among themselves and with the change from baseline in clinical efficacy (assessed using the Simplified Disease Activity Index [SDAI]) at month 3. Results of analyses were presented for each treatment group using descriptive statistics.</p></sec></sec></sec><sec id="acr23004-sec-0013"><sec disp-level="2" id="acr23004-sec-0014"><title>Results</title><sec id="acr23004-sec-0015"><title>Patients</title><p>Patient disposition and demographics have been reported previously <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>. Of 792 patients treated, 315 received tofacitinib 5 mg BID, 318 received 10 mg BID, and 159 received placebo. At month 3, there were 297 patients (94.3%), 295 patients (92.8%), and 149 patients (93.7%) in the respective treatment groups.</p></sec><sec id="acr23004-sec-0016"><title>Baseline values</title><p>Baseline patient demographics were similar across treatment groups: mean age ranged 51.9<bold>&#x02013;</bold>52.7 years, the proportion of women was 77.4<bold>&#x02013;</bold>83.8%, and the mean disease duration was 8.1<bold>&#x02013;</bold>9.9 years <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>. Overall, 6.0<bold>&#x02013;</bold>7.3% of patients had received previous treatment with tumor necrosis factor inhibitor (TNFi) therapy, and 0<bold>&#x02013;</bold>7.6% had received non&#x02010;TNFi biologic agents. The mean number of failed DMARDs was 1.3<bold>&#x02013;</bold>1.4 (4). At baseline, mean PtGA and Pain scores ranged 57.1<bold>&#x02013;</bold>60.2, HAQ DI 1.35<bold>&#x02013;</bold>1.44, SF<bold>&#x02010;</bold>36 PCS and MCS scores 32.0<bold>&#x02013;</bold>32.7 and 40.9<bold>&#x02013;</bold>41.7, respectively, FACIT<bold>&#x02010;</bold>F 28.7<bold>&#x02013;</bold>29.7, and MOS Sleep scores 39.8<bold>&#x02013;</bold>41.1, indicating a substantial burden of disease (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="acr23004-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline values and LSM changes from baseline, percentage of patients with improvement &#x02265;MCID, and NNT at month 3 for PRO measures (full analysis set, no imputation), for patients receiving tofacitinib 5 mg or 10 mg twice daily, or placebo<xref ref-type="fn" rid="acr23004-note-0004">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Baseline</th><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Change from baseline at month 3</th><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Patients reporting improvements &#x02265;MCID at month 3</th><th style="border-bottom:solid 1px #000000" colspan="2" align="center" valign="bottom" rowspan="1">NNT to achieve MCID</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">PRO measure</th><th align="center" valign="bottom" rowspan="1" colspan="1">5 mg (n&#x02009;=&#x02009;312)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">10 mg (n&#x02009;=&#x02009;315)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">placebo (n&#x02009;=&#x02009;158)</th><th align="center" valign="bottom" rowspan="1" colspan="1">5 mg (n&#x02009;=&#x02009;294)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">10 mg (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">placebo (n&#x02009;=&#x02009;147)</th><th align="center" valign="bottom" rowspan="1" colspan="1">5 mg (n&#x02009;=&#x02009;294)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">10 mg (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">placebo (n&#x02009;=&#x02009;148)</th><th align="center" valign="bottom" rowspan="1" colspan="1">5 mg (n&#x02009;=&#x02009;294)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">10 mg (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0005">b</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">PtGA</td><td align="center" valign="top" rowspan="1" colspan="1">59.0&#x02009;&#x000b1;&#x02009;22.9 (n&#x02009;=&#x02009;311)</td><td align="center" valign="top" rowspan="1" colspan="1">60.2&#x02009;&#x000b1;&#x02009;22.5</td><td align="center" valign="top" rowspan="1" colspan="1">57.9&#x02009;&#x000b1;&#x02009;23.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;24.8&#x02009;&#x000b1;&#x02009;1.2 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;28.2&#x02009;&#x000b1;&#x02009;1.3<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;12.5&#x02009;&#x000b1;&#x02009;1.7 (n&#x02009;=&#x02009;148)</td><td align="center" valign="top" rowspan="1" colspan="1">68.6 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">72.6<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">49.3</td><td align="center" valign="top" rowspan="1" colspan="1">5.2 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pain</td><td align="center" valign="top" rowspan="1" colspan="1">57.1&#x02009;&#x000b1;&#x02009;23.8 (n&#x02009;=&#x02009;311)</td><td align="center" valign="top" rowspan="1" colspan="1">58.6&#x02009;&#x000b1;&#x02009;22.2</td><td align="center" valign="top" rowspan="1" colspan="1">57.1&#x02009;&#x000b1;&#x02009;22.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;24.2&#x02009;&#x000b1;&#x02009;1.2 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;26.8&#x02009;&#x000b1;&#x02009;1.3<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;11.4&#x02009;&#x000b1;&#x02009;1.7 (n&#x02009;=&#x02009;148)</td><td align="center" valign="top" rowspan="1" colspan="1">67.9 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">69.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">46.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.6 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAQ DI</td><td align="center" valign="top" rowspan="1" colspan="1">1.44&#x02009;&#x000b1;&#x02009;0.69 (n&#x02009;=&#x02009;311)</td><td align="center" valign="top" rowspan="1" colspan="1">1.43&#x02009;&#x000b1;&#x02009;0.68</td><td align="center" valign="top" rowspan="1" colspan="1">1.35&#x02009;&#x000b1;&#x02009;0.66 (n&#x02009;=&#x02009;157)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.46&#x02009;&#x000b1;&#x02009;0.03 (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.56&#x02009;&#x000b1;&#x02009;0.03<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.21&#x02009;&#x000b1;&#x02009;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">66.1 (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">70.2<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">44.9 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">4.7 (n&#x02009;=&#x02009;292)</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HRQOL (SF&#x02010;36)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PCS</td><td align="center" valign="top" rowspan="1" colspan="1">32.4&#x02009;&#x000b1;&#x02009;7.8</td><td align="center" valign="top" rowspan="1" colspan="1">32.0&#x02009;&#x000b1;&#x02009;7.5</td><td align="center" valign="top" rowspan="1" colspan="1">32.7&#x02009;&#x000b1;&#x02009;7.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x02009;&#x000b1;&#x02009;0.4 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">7.5&#x02009;&#x000b1;&#x02009;0.4 (n&#x02009;=&#x02009;290)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.4&#x02009;&#x000b1;&#x02009;0.6 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">64.5 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">74.1 (n&#x02009;=&#x02009;290)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">47.3 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">5.8 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 (n&#x02009;=&#x02009;290)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MCS</td><td align="center" valign="top" rowspan="1" colspan="1">40.9&#x02009;&#x000b1;&#x02009;12.6</td><td align="center" valign="top" rowspan="1" colspan="1">41.6&#x02009;&#x000b1;&#x02009;11.1</td><td align="center" valign="top" rowspan="1" colspan="1">41.7&#x02009;&#x000b1;&#x02009;11.6</td><td align="center" valign="top" rowspan="1" colspan="1">4.4&#x02009;&#x000b1;&#x02009;0.5 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.4&#x02009;&#x000b1;&#x02009;0.5 (n&#x02009;=&#x02009;290)<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x02009;&#x000b1;&#x02009;0.7 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">58.4 (n&#x02009;=&#x02009;293)<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">53.8 (n&#x02009;=&#x02009;290)<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">41.8 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">6.0 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">8.3 (n&#x02009;=&#x02009;290)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PF</td><td align="center" valign="top" rowspan="1" colspan="1">32.5&#x02009;&#x000b1;&#x02009;9.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.7&#x02009;&#x000b1;&#x02009;9.6</td><td align="center" valign="top" rowspan="1" colspan="1">32.8&#x02009;&#x000b1;&#x02009;9.6</td><td align="center" valign="top" rowspan="1" colspan="1">4.5&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;0.5 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">42.5<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">53.3 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">32.0</td><td align="center" valign="top" rowspan="1" colspan="1">9.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.7 (n&#x02009;=&#x02009;291)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RP</td><td align="center" valign="top" rowspan="1" colspan="1">33.7&#x02009;&#x000b1;&#x02009;9.7</td><td align="center" valign="top" rowspan="1" colspan="1">33.2&#x02009;&#x000b1;&#x02009;9.4</td><td align="center" valign="top" rowspan="1" colspan="1">33.9&#x02009;&#x000b1;&#x02009;9.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">7.4&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">45.9<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">54.1<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">30.6 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BP</td><td align="center" valign="top" rowspan="1" colspan="1">33.4&#x02009;&#x000b1;&#x02009;7.3</td><td align="center" valign="top" rowspan="1" colspan="1">33.9&#x02009;&#x000b1;&#x02009;7.3</td><td align="center" valign="top" rowspan="1" colspan="1">34.2&#x02009;&#x000b1;&#x02009;7.5</td><td align="center" valign="top" rowspan="1" colspan="1">7.3&#x02009;&#x000b1;&#x02009;0.4<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">8.7&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">47.6<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">52.7<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">28.6 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">5.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">GH</td><td align="center" valign="top" rowspan="1" colspan="1">34.0&#x02009;&#x000b1;&#x02009;9.1</td><td align="center" valign="top" rowspan="1" colspan="1">34.3&#x02009;&#x000b1;&#x02009;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">34.7&#x02009;&#x000b1;&#x02009;8.3</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x02009;&#x000b1;&#x02009;0.4<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.6&#x02009;&#x000b1;&#x02009;0.4 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">46.6<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">46.1 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">22.5 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td><td align="center" valign="top" rowspan="1" colspan="1">4.2 (n&#x02009;=&#x02009;291)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VT</td><td align="center" valign="top" rowspan="1" colspan="1">40.8&#x02009;&#x000b1;&#x02009;10.3</td><td align="center" valign="top" rowspan="1" colspan="1">40.9&#x02009;&#x000b1;&#x02009;8.9</td><td align="center" valign="top" rowspan="1" colspan="1">41.3&#x02009;&#x000b1;&#x02009;9.4</td><td align="center" valign="top" rowspan="1" colspan="1">6.3&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.5&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">55.4<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">57.2<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">34.7 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SF</td><td align="center" valign="top" rowspan="1" colspan="1">36.2&#x02009;&#x000b1;&#x02009;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">37.0&#x02009;&#x000b1;&#x02009;10.3</td><td align="center" valign="top" rowspan="1" colspan="1">36.9&#x02009;&#x000b1;&#x02009;11.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.2&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">55.8<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">60.3<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">42.9 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RE</td><td align="center" valign="top" rowspan="1" colspan="1">35.5&#x02009;&#x000b1;&#x02009;13.7</td><td align="center" valign="top" rowspan="1" colspan="1">34.9&#x02009;&#x000b1;&#x02009;13.0</td><td align="center" valign="top" rowspan="1" colspan="1">35.4&#x02009;&#x000b1;&#x02009;13.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;0.6 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x02009;&#x000b1;&#x02009;0.6 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x02009;&#x000b1;&#x02009;0.9 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">39.3 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">47.1 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">34.3 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">20.0 (n&#x02009;=&#x02009;293)</td><td align="center" valign="top" rowspan="1" colspan="1">7.8 (n&#x02009;=&#x02009;291)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MH</td><td align="center" valign="top" rowspan="1" colspan="1">39.9&#x02009;&#x000b1;&#x02009;12.5</td><td align="center" valign="top" rowspan="1" colspan="1">41.1&#x02009;&#x000b1;&#x02009;10.5</td><td align="center" valign="top" rowspan="1" colspan="1">41.5&#x02009;&#x000b1;&#x02009;11.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.8&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.7&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.5&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">50.3<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">52.1<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">29.3 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FACIT&#x02010;F</td><td align="center" valign="top" rowspan="1" colspan="1">29.0&#x02009;&#x000b1;&#x02009;11.1</td><td align="center" valign="top" rowspan="1" colspan="1">28.7&#x02009;&#x000b1;&#x02009;9.5 (n&#x02009;=&#x02009;314)</td><td align="center" valign="top" rowspan="1" colspan="1">29.7&#x02009;&#x000b1;&#x02009;9.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.8&#x02009;&#x000b1;&#x02009;0.5<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;0.5 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.1&#x02009;&#x000b1;&#x02009;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">53.7<xref ref-type="fn" rid="acr23004-note-0008">e</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">63.6 (n&#x02009;=&#x02009;291)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">40.8 (n&#x02009;=&#x02009;147)</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">4.4 (n&#x02009;=&#x02009;291)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOS Sleep</td><td align="center" valign="top" rowspan="1" colspan="1">41.1&#x02009;&#x000b1;&#x02009;20.7</td><td align="center" valign="top" rowspan="1" colspan="1">40.9&#x02009;&#x000b1;&#x02009;18.5 (n&#x02009;=&#x02009;313)</td><td align="center" valign="top" rowspan="1" colspan="1">39.8&#x02009;&#x000b1;&#x02009;18.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.2&#x02009;&#x000b1;&#x02009;0.8 (n&#x02009;=&#x02009;292)<xref ref-type="fn" rid="acr23004-note-0007">d</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.4&#x02009;&#x000b1;&#x02009;0.8 (n&#x02009;=&#x02009;290)<xref ref-type="fn" rid="acr23004-note-0006">c</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.6&#x02009;&#x000b1;&#x02009;1.1 (n&#x02009;=&#x02009;146)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="acr23004-note-0004"><label>a</label><p>Values are: mean&#x02009;&#x000b1;&#x02009;SD (baseline), LSM&#x02009;&#x000b1;&#x02009;SE (month 3), % (patients reporting improvements). LSM&#x02009;=&#x02009;least squares mean; MCID&#x02009;=&#x02009;minimum clinically important difference; NNT&#x02009;=&#x02009;number needed to treat; PRO&#x02009;=&#x02009;patient&#x02010;reported outcome; PtGA&#x02009;=&#x02009;patient global assessment of arthritis; Pain&#x02009;=&#x02009;patient assessment of arthritis pain; HAQ DI&#x02009;=&#x02009;Health Assessment Questionnaire disability index; HRQOL&#x02009;=&#x02009;health&#x02010;related quality of life; SF&#x02010;36&#x02009;=&#x02009;Short Form 36 health survey; PCS&#x02009;=&#x02009;physical component score; MCS&#x02009;=&#x02009;mental component score; PF&#x02009;=&#x02009;physical functioning; RP&#x02009;=&#x02009;role&#x02010;physical; BP&#x02009;=&#x02009;bodily pain; GH&#x02009;=&#x02009;general health; VT&#x02009;=&#x02009;vitality; SF&#x02009;=&#x02009;social functioning; RE&#x02009;=&#x02009;role&#x02010;emotional; MH&#x02009;=&#x02009;mental health; FACIT&#x02010;F&#x02009;=&#x02009;Functional Assessment of Chronic Illness Therapy&#x02013;Fatigue; MOS&#x02009;=&#x02009;Medical Outcomes Study; NA&#x02009;=&#x02009;not available.</p></fn><fn id="acr23004-note-0005"><label>b</label><p>Tofacitinib twice daily.</p></fn><fn id="acr23004-note-0006"><label>c</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 versus placebo.</p></fn><fn id="acr23004-note-0007"><label>d</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></fn><fn id="acr23004-note-0008"><label>e</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acr23004-sec-1017"><title>Month 3 values</title><sec id="acr23004-sec-0017"><title>PtGA</title><p>At month 3, treatment with tofacitinib 5 and 10 mg BID resulted in significantly greater improvements from baseline in PtGA versus placebo (Figure <xref rid="acr23004-fig-0001" ref-type="fig">1</xref>A; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 versus placebo for both), with significantly more (<italic>P</italic>&#x02009;&#x0003c;0.0001) patients reporting improvements &#x02265;MCID; NNTs were 5.2 and 4.3, respectively (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="acr23004-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Least squares mean (LSM) change from baseline over time for: <bold>A,</bold> patient global assessment of arthritis (PtGA), <bold>B,</bold> patient assessment of arthritis pain (Pain), <bold>C,</bold> Short Form 36 health survey (SF&#x02010;36) physical component summary (PCS) score, and <bold>D,</bold>&#x000a0;SF&#x02010;36 mental component summary (MCS) score (full analysis set, no imputation). Horizontal dotted lines represent the minimum clinically important differences (MCIDs). Arrow and vertical dotted line denote completion of advancement to tofacitinib for patients randomized to placebo. Advancement to tofacitinib was at month 3 for placebo nonresponders and at month 6 for all remaining placebo&#x02010;treated patients. BID&#x02009;=&#x02009;twice daily; *&#x02009;=&#x02009;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **&#x02009;=&#x02009;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; ***&#x02009;=&#x02009;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 versus placebo.</p></caption><graphic id="nlm-graphic-1" xlink:href="ACR-69-592-g001"/></fig></sec><sec id="acr23004-sec-0018"><title>Pain</title><p>Patients in both tofacitinib groups reported significantly greater improvements from baseline in Pain at month 3 compared with placebo (Figure <xref rid="acr23004-fig-0001" ref-type="fig">1</xref>B; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 versus placebo for both), with significantly more (<italic>P</italic>&#x02009;&#x0003c; 0.0001) patients reporting improvements &#x02265;MCID; NNTs were 4.6 for tofacitinib 5 mg BID and 4.2 for 10 mg BID (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="acr23004-sec-0019"><title>HAQ DI</title><p>Treatment with tofacitinib 5 and 10 mg BID resulted in significantly greater LSM changes from baseline in HAQ DI versus placebo (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 versus placebo for both) at month 3, with significantly more (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) patients reporting changes &#x02265;MCID; NNTs were 4.7 and 4.0, respectively (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="acr23004-sec-0020"><title>SF&#x02010;36 PCS and MCS</title><p>LSM changes from baseline in SF&#x02010;36 PCS and MCS scores at month 3 were significantly greater for tofacitinib&#x02010;treated patients versus placebo (Figures <xref rid="acr23004-fig-0001" ref-type="fig">1</xref>C and <xref rid="acr23004-fig-0001" ref-type="fig">1</xref>D; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 for PCS, and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for MCS), with significantly more patients reporting improvements in PCS and MCS scores &#x02265;MCID (5 mg BID: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for both; 10 mg BID: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 for PCS, and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for MCS); NNTs were 5.8 and 3.7 for PCS, and 6.0 and 8.3 for MCS, respectively (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="acr23004-sec-0021"><title>SF&#x02010;36 domain scores</title><p>At baseline, mean scores across all SF&#x02010;36 domains indicated substantial impairment in HRQOL compared with an age&#x02010; and sex&#x02010;matched US normative population (Figure <xref rid="acr23004-fig-0002" ref-type="fig">2</xref>). At month 3, improvements reported by patients treated with tofacitinib 5 mg BID in 7 of 8 domains were statistically significant versus placebo (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for all domains except role&#x02010;emotional), and across all 8 domains (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for role&#x02010;emotional) with tofacitinib 10 mg BID (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="acr23004-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Spydergram representing mean overall Short Form 36 health survey domain scores at month 3 (full analysis set, no imputation). Baseline values (orange) were pooled (with weighting) across all 3 treatment groups. BID&#x02009;=&#x02009;twice daily.</p></caption><graphic id="nlm-graphic-3" xlink:href="ACR-69-592-g002"/></fig><p>A significantly greater proportion of patients reported improvements &#x02265;MCID at month 3 across all domains except role&#x02010;emotional with tofacitinib 5 mg BID (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) and all 8 domains with 10 mg BID (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for role&#x02010;emotional); NNTs ranged 4.1&#x02013;20.0 and 4.1&#x02013;7.8, respectively (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="acr23004-sec-0022"><title>FACIT&#x02010;F</title><p>Patients receiving both doses of tofacitinib reported significantly greater improvements (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) from baseline in FACIT&#x02010;F at month 3 versus placebo.</p><p>Significantly more patients reported improvements &#x02265;MCID (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for 5 mg BID, and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 for 10 mg BID); NNTs were 7.7 and 4.4, respectively (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="acr23004-sec-0023"><title>MOS Sleep</title><p>At month 3, significantly greater LSM changes from baseline (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for 5 mg BID, and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 for 10 mg BID) in MOS Sleep score were reported by tofacitinib&#x02010;treated patients compared with placebo (Table <xref rid="acr23004-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec></sec><sec id="acr23004-sec-1024"><title>Month 12 values</title><p>Reported improvements in all PROs were sustained to month 12 (Figure <xref rid="acr23004-fig-0001" ref-type="fig">1</xref>).</p></sec><sec id="acr23004-sec-0024"><title>Correlation analyses</title><p>Correlations were generally positive or negative as expected. For a PRO where an improvement was denoted by positive change from baseline, there was a negative correlation with change in SDAI, for which negative values indicate an improvement, etc. The vast majority of all the correlations were between 0.3 and 0.6 in absolute value. Among domains and components of the SF&#x02010;36, the domains of physical functioning, bodily pain, and vitality had the largest correlations in absolute value with SDAI (0.32&#x02013;0.42) for tofacitinib 5 mg BID and 10 mg BID. The largest correlations in absolute value for PROs with SDAI were observed for PtGA and Pain (0.44&#x02013;0.59), followed by HAQ DI (0.45&#x02013;0.47) and FACIT&#x02010;F (0.35&#x02013;0.41) for tofacitinib 5 mg BID and 10 mg BID.</p></sec></sec></sec><sec id="acr23004-sec-0025"><sec disp-level="2" id="acr23004-sec-0026"><title>Discussion</title><p>PROs assessing HRQOL and fatigue are considered important in RCTs of RA treatments because, in addition to being incorporated into composite disease activity measures, they reflect aspects of disease impact (such as physical function, physical and emotional wellbeing, pain, and fatigue) that are likely more important to patients than joint counts or laboratory tests <xref rid="acr23004-bib-0002" ref-type="ref">2</xref>.</p><p>In this study, baseline SF&#x02010;36 scores reflected a substantial burden of disease compared with a benchmark age&#x02010; and sex&#x02010;matched normative population. Treatment with tofacitinib 5 and 10 mg BID in combination with DMARDs resulted in statistically significant improvements versus placebo at month 3 in PtGA, Pain, HAQ DI, SF&#x02010;36 PCS and MCS scores, 7 and 8 SF&#x02010;36 domains, respectively, FACIT&#x02010;F, and MOS Sleep. These improvements resulted in generally small, clinically meaningful NNTs and were sustained to month 12. Sleep disturbance is associated with disease activity and pain in RA and affects mood <xref rid="acr23004-bib-0010" ref-type="ref">10</xref>; it is encouraging, therefore, that in this trial, reported improvements in HRQOL and fatigue were accompanied by similar changes in MOS Sleep. Together, these results demonstrate a broad benefit of tofacitinib treatment on the physical and mental burden of RA.</p><p>The clinical importance of these results is supported by significantly greater proportions of patients in both tofacitinib treatment groups reporting improvements &#x02265;MCID, with correspondingly small NNTs. With the exception of the role&#x02010;emotional domain with the 5 mg BID dose, reported improvements in PROs were statistically significant and clinically meaningful with both tofacitinib doses, generally higher with 10 mg BID, and consistent with the primary results of the trial <xref rid="acr23004-bib-0004" ref-type="ref">4</xref>.</p><p>Results of this trial are also consistent with those reported in the other phase III RCTs of tofacitinib in RA, where statistically significant and clinically meaningful improvements across a range of PROs were reported in methotrexate&#x02010;inadequate responders (ORAL Standard trial [NCT00853385]) <xref rid="acr23004-bib-0008" ref-type="ref">8</xref> and biologic DMARD&#x02010;inadequate responders (bDMARD&#x02010;IR; ORAL Step trial [NCT00960440]) <xref rid="acr23004-bib-0007" ref-type="ref">7</xref>. Data from the present trial are also consistent with those from RCTs of bDMARDs in DMARD&#x02010;IR populations, including adalimumab <xref rid="acr23004-bib-0011" ref-type="ref">11</xref>, etanercept <xref rid="acr23004-bib-0012" ref-type="ref">12</xref>, golimumab <xref rid="acr23004-bib-0013" ref-type="ref">13</xref>, infliximab <xref rid="acr23004-bib-0014" ref-type="ref">14</xref>, and tocilizumab <xref rid="acr23004-bib-0015" ref-type="ref">15</xref>.</p><p>A limitation of this study was the short duration of placebo exposure, with advancement from placebo occurring in 2 stages at months 3 and 6. Therefore, although improvements in PROs were reported to month 12, direct comparison with all placebo&#x02010;treated patients beyond month 3 was not possible. A second limitation was that enrollment in the study was not stratified by background DMARD therapy, which varied among patients, with most receiving methotrexate, alone or in combination with other conventional DMARDs. In this analysis, missing data were not imputed; however, LSM change from baseline was calculated and is considered to be less sensitive to missing data than use of arithmetic means.</p><p>In conclusion, this RCT demonstrated that tofacitinib 5 and 10 mg BID in combination with DMARDs resulted in significant and clinically meaningful improvements versus placebo across a broad range of PROs in conventional&#x02010;and bDMARD&#x02010;IR patients with active RA. These changes from baseline were sustained through month 12 and provide further evidence that treatment with tofacitinib improves pain, physical function, HRQOL, fatigue, and sleep, in addition to underlying disease activity.</p></sec></sec><sec id="acr23004-sec-0028"><title>AUTHOR CONTRIBUTIONS</title><p>All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Wallenstein had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><sec id="acr23004-sec-0029"><title>Study conception and design</title><p>Strand, Kremer, Gruben, Krishnaswami, Zwillich, Wallenstein.</p></sec><sec id="acr23004-sec-0030"><title>Acquisition of data</title><p>Kremer.</p></sec><sec id="acr23004-sec-0031"><title>Analysis and interpretation of data</title><p>Strand, Kremer, Gruben, Krishnaswami, Zwillich, Wallenstein.</p></sec></sec><sec id="acr23004-sec-0032"><title>ROLE OF THE STUDY SPONSOR</title><p>This study was funded by Pfizer Inc. The study was designed by the Pfizer Inc. authors in collaboration with the academic authors. Dr. Gruben performed data and statistical analyses. Medical writing support under the direction of the authors was provided by Daniel Binks, PhD, of Complete Medical Communications and funded by Pfizer Inc. All authors were involved in the interpretation of data and manuscript drafting, reviewing, and development. Publication of this article was not contingent upon approval by Pfizer Inc.</p></sec></body><back><ack id="acr23004-sec-0027"><title>ACKNOWLEDGMENTS</title><p>The authors thank the patients, investigators, and study team who were involved in the ORAL Sync study.</p></ack><ref-list content-type="cited-references"><title>REFERENCES</title><ref id="acr23004-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acr23004-cit-0001">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Singh</surname>
<given-names>JA.</given-names>
</string-name>
<article-title>Newer biological agents in rheumatoid arthritis: impact on health&#x02010;related quality of life and productivity</article-title>. <source>Drugs</source>
<year>2010</year>;<volume>70</volume>:<fpage>121</fpage>&#x02013;<lpage>45</lpage>.
<pub-id pub-id-type="pmid">20108988</pub-id></mixed-citation></ref><ref id="acr23004-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acr23004-cit-0002">
<string-name>
<surname>Kirwan</surname>
<given-names>JR</given-names>
</string-name>, 
<string-name>
<surname>Hewlett</surname>
<given-names>SE</given-names>
</string-name>, 
<string-name>
<surname>Heiberg</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</string-name>, 
<string-name>
<surname>Carr</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Hehir</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7</article-title>. <source>J Rheumatol</source>
<year>2005</year>;<volume>32</volume>:<fpage>2250</fpage>&#x02013;<lpage>6</lpage>.
<pub-id pub-id-type="pmid">16265712</pub-id></mixed-citation></ref><ref id="acr23004-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acr23004-cit-0003">
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Kremer</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Cush</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Schulze&#x02010;Koops</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Connell</surname>
<given-names>CA</given-names>
</string-name>, 
<string-name>
<surname>Bradley</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Placebo&#x02010;controlled trial of tofacitinib monotherapy in rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>367</volume>:<fpage>495</fpage>&#x02013;<lpage>507</lpage>.
<pub-id pub-id-type="pmid">22873530</pub-id></mixed-citation></ref><ref id="acr23004-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acr23004-cit-0004">
<string-name>
<surname>Kremer</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>
<given-names>ZG</given-names>
</string-name>, 
<string-name>
<surname>Hall</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Genovese</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Martin&#x02010;Mola</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Tofacitinib in combination with nonbiologic disease&#x02010;modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</article-title>. <source>Ann Intern Med</source>
<year>2013</year>;<volume>159</volume>:<fpage>253</fpage>&#x02013;<lpage>61</lpage>.
<pub-id pub-id-type="pmid">24026258</pub-id></mixed-citation></ref><ref id="acr23004-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acr23004-cit-0005">
<string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, 
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Hall</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Wilkinson</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Bradley</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Gruben</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Tofacitinib versus methotrexate in rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2014</year>;<volume>370</volume>:<fpage>2377</fpage>&#x02013;<lpage>86</lpage>.
<pub-id pub-id-type="pmid">24941177</pub-id></mixed-citation></ref><ref id="acr23004-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acr23004-cit-0006">
<string-name>
<surname>Van der Heijde</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, 
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Keystone</surname>
<given-names>E</given-names>
</string-name>, 
<string-name>
<surname>Kremer</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Zerbini</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Tofacitinib (CP&#x02010;690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve&#x02010;month data from a twenty&#x02010;four&#x02010;month phase III randomized radiographic study</article-title>. <source>Arthritis Rheum</source>
<year>2013</year>;<volume>65</volume>:<fpage>559</fpage>&#x02013;<lpage>70</lpage>.
<pub-id pub-id-type="pmid">23348607</pub-id></mixed-citation></ref><ref id="acr23004-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acr23004-cit-0007">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Burmester</surname>
<given-names>GR</given-names>
</string-name>, 
<string-name>
<surname>Zerbini</surname>
<given-names>CA</given-names>
</string-name>, 
<string-name>
<surname>Mebus</surname>
<given-names>CA</given-names>
</string-name>, 
<string-name>
<surname>Zwillich</surname>
<given-names>SH</given-names>
</string-name>, 
<string-name>
<surname>Gruben</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>et</surname>
<given-names>al.</given-names>
</string-name>
<article-title>Tofacitinib with methotrexate in third&#x02010;line treatment of patients with active rheumatoid arthritis: patient&#x02010;reported outcomes from a phase III trial</article-title>. <source>Arthritis Care Res (Hoboken)</source>
<year>2015</year>;<volume>67</volume>:<fpage>475</fpage>&#x02013;<lpage>83</lpage>.
<pub-id pub-id-type="pmid">25186034</pub-id></mixed-citation></ref><ref id="acr23004-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acr23004-cit-0008">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>van Vollenhoven</surname>
<given-names>RF</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, 
<string-name>
<surname>Fleischmann</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Zwillich</surname>
<given-names>SH</given-names>
</string-name>, 
<string-name>
<surname>Gruben</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Tofacitinib or adalimumab versus placebo: patient&#x02010;reported outcomes from a phase 3 study of active rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source>
<year>2016</year>;<volume>55</volume>:<fpage>1031</fpage>&#x02013;<lpage>41</lpage>.
<pub-id pub-id-type="pmid">26929445</pub-id></mixed-citation></ref><ref id="acr23004-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acr23004-cit-0009">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Boers</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Idzerda</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Kirwan</surname>
<given-names>JR</given-names>
</string-name>, 
<string-name>
<surname>Kvien</surname>
<given-names>TK</given-names>
</string-name>, 
<string-name>
<surname>Tugwell</surname>
<given-names>PS</given-names>
</string-name>, et al. <article-title>It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible: response criteria and the importance of change at OMERACT 10</article-title>. <source>J Rheumatol</source>
<year>2011</year>;<volume>38</volume>:<fpage>1720</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="pmid">21807792</pub-id></mixed-citation></ref><ref id="acr23004-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acr23004-cit-0010">
<string-name>
<surname>Wolfe</surname>
<given-names>F</given-names>
</string-name>, 
<string-name>
<surname>Michaud</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>
<given-names>T.</given-names>
</string-name>
<article-title>Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales</article-title>. <source>J Rheumatol</source>
<year>2006</year>;<volume>33</volume>:<fpage>1942</fpage>&#x02013;<lpage>51</lpage>.
<pub-id pub-id-type="pmid">16960928</pub-id></mixed-citation></ref><ref id="acr23004-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acr23004-cit-0011">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</string-name>, 
<string-name>
<surname>Cifaldi</surname>
<given-names>MA</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Roy</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Revicki</surname>
<given-names>D.</given-names>
</string-name>
<article-title>Health&#x02010;related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study</article-title>. <source>J Rheumatol</source>
<year>2012</year>;<volume>39</volume>:<fpage>63</fpage>&#x02013;<lpage>72</lpage>.
<pub-id pub-id-type="pmid">22045836</pub-id></mixed-citation></ref><ref id="acr23004-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acr23004-cit-0012">
<string-name>
<surname>Van der Heijde</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Klareskog</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Singh</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Tornero</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Melo&#x02010;Gomes</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Codreanu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial</article-title>. <source>Ann Rheum Dis</source>
<year>2006</year>;<volume>65</volume>:<fpage>328</fpage>&#x02013;<lpage>34</lpage>.
<pub-id pub-id-type="pmid">16079172</pub-id></mixed-citation></ref><ref id="acr23004-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acr23004-cit-0013">
<string-name>
<surname>Genovese</surname>
<given-names>MC</given-names>
</string-name>, 
<string-name>
<surname>Han</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Keystone</surname>
<given-names>EC</given-names>
</string-name>, 
<string-name>
<surname>Hsia</surname>
<given-names>EC</given-names>
</string-name>, 
<string-name>
<surname>Buchanan</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Gathany</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Effect of golimumab on patient&#x02010;reported outcomes in rheumatoid arthritis: results from the GO&#x02010;FORWARD study</article-title>. <source>J Rheumatol</source>
<year>2012</year>;<volume>39</volume>:<fpage>1185</fpage>&#x02013;<lpage>91</lpage>.
<pub-id pub-id-type="pmid">22505702</pub-id></mixed-citation></ref><ref id="acr23004-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acr23004-cit-0014">
<string-name>
<surname>Maini</surname>
<given-names>RN</given-names>
</string-name>, 
<string-name>
<surname>Breedveld</surname>
<given-names>FC</given-names>
</string-name>, 
<string-name>
<surname>Kalden</surname>
<given-names>JR</given-names>
</string-name>, 
<string-name>
<surname>Smolen</surname>
<given-names>JS</given-names>
</string-name>, 
<string-name>
<surname>Furst</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Weisman</surname>
<given-names>MH</given-names>
</string-name>, et al. <article-title>Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate</article-title>. <source>Arthritis Rheum</source>
<year>2004</year>;<volume>50</volume>:<fpage>1051</fpage>&#x02013;<lpage>65</lpage>.
<pub-id pub-id-type="pmid">15077287</pub-id></mixed-citation></ref><ref id="acr23004-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acr23004-cit-0015">
<string-name>
<surname>Strand</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Burmester</surname>
<given-names>GR</given-names>
</string-name>, 
<string-name>
<surname>Ogale</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Devenport</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>John</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Emery</surname>
<given-names>P.</given-names>
</string-name>
<article-title>Improvements in health&#x02010;related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24&#x02010;week randomized controlled RADIATE study</article-title>. <source>Rheumatology (Oxford)</source>
<year>2012</year>;<volume>51</volume>:<fpage>1860</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="pmid">22753773</pub-id></mixed-citation></ref></ref-list></back></article>